Weekly Investment Analysts’ Ratings Changes for Enhabit (EHAB)

Several analysts have recently updated their ratings and price targets for Enhabit (NYSE: EHAB):

• 12/22/2025 – Enhabit had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/16/2025 – Enhabit had its “buy” rating reaffirmed by analysts at Jefferies Financial Group Inc..
• 12/16/2025 – Enhabit had its “buy” rating reaffirmed by analysts at Citigroup Inc..
• 12/15/2025 – Enhabit had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – Enhabit had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/1/2025 – Enhabit had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/25/2025 – Enhabit had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/19/2025 – Enhabit had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/13/2025 – Enhabit had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.

Enhabit, Inc (NYSE: EHAB) is a national provider of home-based healthcare services, offering a continuum of care designed to support patients in the comfort of their own homes. The company’s core mission is to deliver personalized clinical and non-clinical services that help individuals recover from illness or injury, manage chronic conditions, and, when necessary, receive compassionate end-of-life care. Enhabit’s business model centers on combining skilled clinical care with patient-centric service coordination to optimize outcomes and enhance the overall care experience.

The company’s service portfolio includes skilled nursing, physical, occupational and speech therapies, personal care assistance, palliative care and hospice services.